Longitudinal Assessment of Circulating Tumor Cells and Outcome in Small Cell Lung Cancer: A Sub-Study of RASTEN—A Randomized Trial with Low Molecular Weight Heparin
Open Access
Abstract
Circulating tumor cells (CTCs) may provide a liquid biopsy approach to disease monitoring in small cell lung cancer (SCLC), a particularly aggressive tumor subtype. Yet, the prognostic role of CTCs during and after treatment in relation to baseline remains ill-defined. Here, we assessed the value of longitudinal CTC analysis and the potential of low-molecular-weight heparin (LMWH) to reduce CTC abundance in SCLC patients from a randomized trial (RASTEN). Blood samples were collected at baseline, before chemotherapy Cycle 3, and at 2-month follow-up from 42 patients in total, and CTCs were quantified using the FDA-approved CellSearch system. We found a gradual decline in CTC count during and after treatment, independently of the addition of LMWH to standard therapy. Detectable CTCs at baseline correlated significantly to reduced survival compared to undetectable CTCs (unadjusted hazard ratio (HR) of 2.75 (95% CI 1.05–7.20; p = 0.040)). Furthermore, a persistent CTC count at 2-month follow-up was associated with a HR of 4.22 (95% CI 1.20–14.91; p = 0.025). Our findings indicate that persistently detectable CTCs during and after completion of therapy offer further prognostic information in addition to baseline CTC, suggesting a role for CTC in the individualized management of SCLC.Keywords
Funding Information
- Cancerfonden (CAN 20 0745, VR-MH 2018-02562)
- Vetenskapsrådet (CAN 20 0745, VR-MH 2018-02562)
- Fru Berta Kamprad Foundation (CAN 20 0745, VR-MH 2018-02562)
- Skåne University Hospital donation funds (CAN 20 0745, VR-MH 2018-02562)
- Governmental funding of clinical research within the national health services (CAN 20 0745, VR-MH 2018-02562)
- Regional research support, Southern Healthcare Region Sweden (CAN 20 0745, VR-MH 2018-02562)
This publication has 44 references indexed in Scilit:
- Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agentsProceedings of the National Academy of Sciences, 2012
- A Systematic Analysis of Efficacy of Second-Line Chemotherapy in Sensitive and Refractory Small-Cell Lung CancerJournal of Thoracic Oncology, 2012
- Circulating Tumor Cell as a Diagnostic Marker in Primary Lung CancerClinical Cancer Research, 2009
- Role of Tissue Factor in CancerJournal of Clinical Oncology, 2009
- Evaluation of Circulating Tumor Cells and Serological Cell Death Biomarkers in Small Cell Lung Cancer Patients Undergoing ChemotherapyThe American Journal of Pathology, 2009
- Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results DatabaseJournal of Clinical Oncology, 2006
- Incidence of venous thrombosis in a large cohort of 66 329 cancer patients: results of a record linkage studyJournal of Thrombosis and Haemostasis, 2006
- Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant DiseasesClinical Cancer Research, 2004
- A randomized clinical trial of combination chemotherapy with and without low‐molecular‐weight heparin in small cell lung cancerJournal of Thrombosis and Haemostasis, 2004
- Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and anti-metastatic propertiesGlycobiology, 1996